Kymera Therapeutics, Inc.
KYMR
Rang in aandelen
#2179
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Aandeelprijs
$114.06
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$9.38B
Verandering (1 dag)
5.54%
Verandering (1 jaar)
95.57%
Land
US
Handel Kymera Therapeutics, Inc. (KYMR)
Categorie
Healthcare
Winst voor Kymera Therapeutics, Inc. (KYMR)
Winst in Jun 2026 TTM: $-299.87M
Volgens de meest recente financiële verslagen van Kymera Therapeutics, Inc. bedraagt de huidige winst van het bedrijf $-299.87M. In 2023 behaalde het bedrijf een winst van $-146.96M, een stijging ten opzichte van de winst van 2022, die $-154.81M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Kymera Therapeutics, Inc. van 2018 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-299.87M | 33.96% |
| 2024 | $-223.86M | 52.32% |
| 2023 | $-146.96M | -5.07% |
| 2022 | $-154.81M | 54.47% |
| 2021 | $-100.22M | 119.81% |
| 2020 | $-45.59M | 10.54% |
| 2019 | $-41.25M | 92.14% |
| 2018 | $-21.47M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -1,859.04% |
US
|
|
| $-3.09B | 929.44% |
US
|
|
| $-4.02B | 1,239.30% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -750.49% |
NL
|
